Seneschal Advisors’s Gilead Sciences GILD Stock Holding History

Seneschal Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.3K	Hold	110	–	–	0.01%	129
2025 Q4	$13.5K	Hold	110	–	–	0.01%	137
2025 Q3	$12.2K	Buy	+110	New	+$12.5K	0.01%	141

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Seneschal Advisors's GILD Position: Q1 2026 in Review

Seneschal Advisors held its Gilead Sciences (GILD) position steady in Q1 2026 at 110 shares worth $15.3K. The position accounts for 0.01% of the portfolio, ranked #129.

Seneschal Advisors first reported a position in GILD in Q3 2025 and has held it in 3 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Seneschal Advisors held 110 shares of Gilead Sciences worth $15.3K as of Q1 2026.
Seneschal Advisors left its Gilead Sciences share count unchanged in Q1 2026.
Gilead Sciences made up 0.01% of Seneschal Advisors's portfolio in Q1 2026, its #129 holding.
Seneschal Advisors first reported a position in Gilead Sciences in Q3 2025 and has held it in 3 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Seneschal Advisors's 13F filing for Q1 2026, filed 8 May 2026.